MINI REVIEW Cancer in the Fourth Dimension: What Is the Impact of Circadian Disruption? 1455
M. Pariollaud and K.A. Lamia

RESEARCH BRIEFS Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer 1465

Précis: Higher risk of death from COVID-19 among patients with cancer was correlated with male sex, greater age, presence of multiple comorbidities, advanced-stage disease, and active disease; there was no association between risk and anticancer treatment.

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance 1475

Précis: Reversion mutations that cause resistance of initially homologous recombination–deficient tumors to PARP inhibitors and platinum-based chemotherapies often affect BRCA1/2 and may lead to susceptibility to immunotherapy.

Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer 1489
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.............. 1528


Précis: In a phase I trial of patients with advanced solid tumors, combination treatment with the PARP inhibitor olaparib and the AKT inhibitor capivasertib showed early signs of efficacy, supporting preclinical observations of synergy.

Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia.................. 1544


Précis: CD39-expressing acute myeloid leukemia cells expanded after cytarabine treatment and activated the cell survival-promoting mitochondrial stress response, leading to relapse with chemotherapy-resistant disease.

Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes.......... 1566


Précis: A new mouse model enabled ascertainment of molecular details of the two pancreatic ductal adenocarcinoma subtypes, revealing that the transition from a slow-growing to a fast-growing tumor is marked by activation of KRAS signaling genes.

See commentary, p. 1448
ON THE COVER
Pancreatic ductal adenocarcinoma (PDAC) comes in two subtypes, one referred to as basal-like (or squamous) and the other denoted classic (or progenitor). The two types have markedly different gene-expression profiles and carry different prognoses, with basal-like PDAC being more aggressive. Miyabayashi and colleagues developed a novel mouse model in which PDAC organoids are engrafted into the pancreatic ducts, where PDACs develop in humans, and PDACs grown in this way recapitulated the two subtypes observed in patients. Analyses of these tumors revealed that cell plasticity-mediated switching between the subtypes could occur, and the transition from a classic-like to a basal-like subtype was associated with activation of genes in the KRAS pathway. For more information, see the article by Miyabayashi and colleagues on page 1566.